Navigation Links
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
Date:12/2/2008

CARLSBAD, Calif., Dec. 2 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the RBC Capital Markets 2008 Healthcare Conference scheduled to take place at the Westin New York Hotel at Times Square on December 10-11, 2008.

Sam Riccitelli, COO and executive vice president of Genoptix, will take part in a panel discussion at the conference on Wednesday, December 10, beginning at approximately 12:30 p.m. EST. Mr. Riccitelli will provide an overview of the Company's specialized diagnostic laboratory service offerings, growth strategies and past operational performance.

The panel discussion on personalized medicine is expected to last approximately 55 minutes, including an audience Q&A session, and will be web cast live and made accessible through the investor relations section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. A replay will also be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
2. Genoptix Announces the Addition of New Members to Board of Directors
3. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
4. Genoptix Reports Strong Financial Results for First Quarter 2008
5. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
6. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
9. Genoptix Announces Pricing of Secondary Public Offering
10. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
11. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)... Reward and recognise service excelle...ctober. , London (PRWeb U...oughout the UK are being urged to celebrate the im...art in National Customer Service Week - 5-11 Octob... business to the corner shop and local authority s...
(Date:7/3/2009)...tner through divorce or death in middle age may tr... July 2 (HealthDay News) -- Middle-aged adults who...a or Alzheimer,s disease later in life compared to... the risk is three times higher among those who ar... Swedish and Finnish researchers. , The study i...
(Date:7/3/2009)...GHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech,...R&D outsourcing company in Shanghai,China an...d Senior Vice,President of Chemistry Services. ,... Neurocrine Biosciences, a drug,discovery and dev...rom a staff,scientist to Senior Director of Medic...
(Date:7/3/2009)... ReverseAges.com launches new content... adrenal fatigue, and how to best deal with these ...o, CA (PRWEB) July 3, 2009 -- ReverseAges.com has ...es explain the dangers of common health issues suc...aused by a variety of factors, and the new content...
Breaking Medicine News(10 mins):Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...y of what causes the fatal autoimmune disease Syst...entification of a possible genetic link. Researche...ol of Medicine (UCSD) uncovered the possible genet...iona journal say that a gene has been identified i...
...ing by the researchers now reckons the evil effect...rus protects against the development of brain tumo...done a couple of years ago , an unexpected finding...our called gliomas were less likely to have had va...
... cancer is the most common cancer in men at the ag...y Tucker of the Prince of Wales Hospital and Dr Je... located a gene which increases men's risk of test...nherited from their mothers. The newly located gen...
... working on the 10-year international Human Genome...re believed to carry the highest concentration of ..., 3 are believed to be associated with genetic dis...arch at the Wellcome Trust's Sanger Centre, near C...
Other Medicine News:Health News:Identification of gene 2
(Date:6/26/2009)... BRIDGEWATER, N.J., June 26 /PRNewswire-FirstCall/...Y ) has just been made aware of data associated wi...tries. The results of these data clearly show that...a possible causal relationship between Lantus(R) (...urrence of malignancies, as the authors of the stu...
(Date:6/25/2009)... - Thirteen Renowned Medical Experts Slated to Att...Y., June 25 The first national sym...nergy drinks will be held next week in New York Ci...earch and analysis from their respective fields. ...ation and research on the health impacts that the ...
(Date:6/25/2009)... ACUROX(R) and EMBEDA (TM) Data Highlighted at the...ting , , RENO, Nev., June 25 ...ounced that the Company is presenting safety and e...1), two novel opioid analgesic formulations that a...he College on Problems of Drug Dependence. King i...
(Date:6/24/2009)... Preliminary top-line results of second Phase III ...d fatigue and improved daily function in fibromyal...ase III study , , PALO ALTO, Calif., and BRUSSE...se, regulated information -- Jazz Pharmaceuticals...s: UCB) announced today positive preliminary top-l...
Breaking Medicine Technology:Sanofi-aventis Stands Behind the Safety of Lantus(R) 2Sanofi-aventis Stands Behind the Safety of Lantus(R) 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 2Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 3Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 4Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 5Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints 6Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare Related E 24000 1Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare Related E 24000 2Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare Related E 24000 3AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 1AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 2AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 3AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 4Family resources parenting quality influence childrens early cognitive development 23994 1Family resources parenting quality influence childrens early cognitive development 23994 2Tumor inhibiting protein could be effective in treating leukemia 4038 1Tumor inhibiting protein could be effective in treating leukemia 4038 2
...arch 12, 2007 /PRNewswire-FirstCall/ --,InB:Biotec...iary of,Integrated BioPharma, Inc. , today announc...against HPV, anthrax and plague made,using INBP,s ...The,studies were conducted by the Fraunhofer USA C...act Research Organization led by Dr.,Vidadi Yusibo...
...ch 13, 2007--Active Biotech AB,(Stockholm:ACTI.ST)...Q:CHTP) has performed a first human micro-dosing t...as to determine the pharmacokinetic,characteristic...ed,in healthy volunteers. , The study demonstrated...pharmacokinetic properties that make it well,suita...
Other Medicine Technology:Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results 2Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2
Sterile perfluorocarbon for intraocular Application.
Alcon offers medical grade perfluoropropane (C3F8) intraocular gases for ophthalmological use.
Round knurled handle. Overall length 130 mm.
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses.
Medicine Products: